Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Asuragen introduces ARQ IS Calibrator Panels to improve BCR-ABL1 testing for CML

Asuragen, Inc. announced today that it has commercially launched the ARQ IS Calibrator Panels (RUO), intended to aid laboratories with standardization of BCR-ABL1 quantitative measurements on the International Scale.

31 Oct 2011

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Veronica Cappalonga, 28, knows a lot about living with cancer. Diagnosed at age 6 with leukemia and at 22 with a malignant brain tumor, the Los Angeles (Mar Vista area) resident will walk in the Nov. 6 Heroes of Hope Race for Brain Tumor Research - not only to help fundraise, but also to show that survivors can fight these diseases with dignity.

29 Oct 2011

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.

27 Oct 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

UCR biology professor inducted into American Academy of Arts and Sciences

David Reznick, a professor of biology at the University of California, Riverside, was among 179 of the nation's most influential artists, scientists, scholars, authors, and institutional leaders who were inducted into the American Academy of Arts and Sciences at a ceremony in Cambridge, Mass., on Oct. 1.

22 Oct 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

Biomarker can help identify GVHD in cancer patients after hematopoietic stem cell transplant

A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.

22 Oct 2011

Two proteins bind together to ignite and sustain malignant brain tumors

Two previously unassociated proteins known to be overly active in a variety of cancers bind together to ignite and sustain malignant brain tumors, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports this week in the journal Cancer Cell.

22 Oct 2011

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

NEP successfully inserts specific doses of anti-cancer gene into leukemia cells

For the first time, researchers have found a way to inject a precise dose of a gene therapy agent directly into a single living cell without a needle.

18 Oct 2011

Delayed appendectomies may increase likelihood of complications in children

An in-hospital delay of appendicitis treatment beyond two days was linked to an increased likelihood of complications, including perforation and abscess formation; longer hospitalization; increased costs; and more rarely, death, according an abstract presented Saturday, Oct. 15 at the American Academy of Pediatrics (AAP) National Conference and Exhibition in Boston.

15 Oct 2011

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.

14 Oct 2011

Scientisits uncover evidence of powerful new cancer genetic networks

In findings with major implications for the genetics of cancer and human health, researchers at Beth Israel Deaconess Medical Center (BIDMC) and two other science teams in New York City and Rome have uncovered evidence of powerful new genetic networks and showed how it may work to drive cancer and normal development.

14 Oct 2011

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Manhattan Scientifics announced today that the National Cancer Institute (NCI) has funded a grant for its Senior Scientific, LLC unit, for the use of its proprietary, highly precise magnetic cancer cell measurement in leukemia research for determining the progress of cancer treatment.

14 Oct 2011

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.

14 Oct 2011

SFDA approves China Medical Technologies' colorectal cancer assay

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that China's State Food and Drug Administration has approved the Company's real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog assay as a companion diagnostic test for the use of a targeted drug for the treatment of colorectal cancer patients.

13 Oct 2011

Viewpoints: The value of testing for prostate cancer; rewards for transplant donors; Calif.'s medical marijuana problem

For men older than 50, a simple blood test to screen for prostate cancer is as much a part of annual physicals as weigh-ins and stethoscopes. The PSA test is painless, inexpensive and the only way to detect the disease - the most common male cancer - before symptoms turn up.

12 Oct 2011

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR Biotech, Inc. today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons.

12 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

Loyola's SSOM receives $100,000 grant for research into pediatric leukemia

Loyola University Chicago Stritch School of Medicine (SSOM) today received a $100,000 grant to support research to treat an aggressive form of pediatric leukemia.

4 Oct 2011